

3 April 2025

## **PROF. MICHAEL BARNES MD. FRCP APPOINTED TO BIOXYNE ADVISORY BOARD**

Bioxyne Limited (“BXN” or the “Company”) is pleased to announce that leading consultant neurologist, Professor Michael Barnes *MD. FRCP* (“Mike” or “Prof Barnes”), president of the Cannabis Industry Council, president of the Medical Cannabis Clinicians Society (UK) has joined the BXN advisory board.

Prof Barnes will advise the Company as it develops its medicinal cannabis business in the UK.

Prof Barnes was previously an advisor to GW Pharmaceuticals ([NASDAQ:JAZZ](#)) during their development and registration of Sativex® and Epidiolex®, which are registered cannabis based medicines with annualized sales of ~AUD\$1.5 billion.

The Company will also leverage Prof Barnes’s experience in registering medicines for marketing authorization, which will allow it to distribute its products through traditional prescriber channels, without the need for special access or authorized prescriber pathways.

**Sam Watson, Bioxyne CEO comments:** “We have been working with Mike for several months in the UK; it is an honour to formalize the relationship and to welcome him to the BXN advisory board. Mike’s insight and experience are essential as Bioxyne expands its presence globally and prepares to pursue registration of its products, which is a multibillion dollar per year opportunity as shown by JAZZ’s success with their registered cannabis medicines. This is a natural step forward for Bioxyne and BLS, and a challenge we look forward to pursuing with Mike’s assistance.”

### **About Professor Barnes**

Author of more than a dozen authoritative books and 100 academic papers, Prof. Barnes has dedicated the latter part of his career to the development of medical cannabis awareness, education and clinical excellence. He brings his expertise to global medical cannabis organisations, educates clinicians and patients and advocates for a pragmatic and robust approach to medical cannabis prescribing as the UK industry growth.

In 2018, Prof. Barnes was the first UK doctor to successfully negotiate a medical cannabis prescription from the Government, for Alfie Dingley.

Prof Barnes was the Founder Chair of the Medical Cannabis Clinicians Society, a not-for-profit society providing training, expert guidance & peer support for clinicians prescribing life-changing medical cannabis treatments in the UK. He also is chair of the Cannabis Industry Council.

As Honorary President of the Cannabis Industry Council and the Medical Cannabis Clinicians Society, Mike is connected with every medical cannabis prescriber and clinic in the UK. He also advises government on legislation relating to the medical cannabis industry.

As a consultant neurologist and medical cannabis expert, Professor Mike Barnes has dedicated his career to the development of neurological rehabilitation and medical cannabis treatments and education. Over 30 years within senior roles in the NHS and independent neurorehabilitation services, Professor Barnes became interested in the medical applications of cannabis with the progression of Sativex to market. He signed off an expert report to the Medicines and Healthcare products Regulatory Agency which was subsequently used, with more recent evidence, to establish Sativex - a cannabis extract which alleviates symptoms of multiple sclerosis - in over 30 countries.

This announcement has been approved for release by the Board.

**For further information contact:**


Sam Watson  
Managing Director  
Bioxyne Limited

[sam@breathelifesciences.com](mailto:sam@breathelifesciences.com)

Guy Robertson  
Chief Financial Officer  
Bioxyne Limited

[guy@bioxyne.com](mailto:guy@bioxyne.com)





*Bioxyne Activity Worldwide*



## About Bioxyne Ltd.

**Bioxyne Limited (ASX:BXN)** is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

## About Breathe Life Sciences (BLS)

**Breathe Life Sciences (“BLS”)** is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA..

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacturing final dose form finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in the manufacture of novel / investigational therapeutic goods. .

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow. Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- c) White label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- d) Research and development; and
- e) Direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson®
  - **United Kingdom:** [drwatsoncbd.com](https://www.drwatsoncbd.com)



- **Japan:** [nolcbn.com](http://nolcbn.com)
- f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

**Corporate:** <https://bioxyne.com>

**Australia:** <https://bls.com.au>;

**International:** <https://breathelifesciences.com>

